News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. PDF Version. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
News Release - Eli Lilly and Company
WEBJul 14, 2023 · INDIANAPOLIS and NEW YORK, July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
FDA approves Eli Lilly’s Zepbound, a weight loss drug ... - NBC News
WEBNov 8, 2023 · The FDA has approved Zepbound, an injectable weight loss drug from Eli Lilly that helped people lose up to 52 lbs in 16 months during clinical trials.
Lilly's Alzheimer’s drug that can slow disease gets ... - NBC News
WEBJun 10, 2024 · A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB16 hours ago · The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's ...
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
News Release - Eli Lilly and Company
WEBMay 24, 2024 · Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines. May 24, 2024. Download PDF. Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history.
Lilly launches lower-price weight loss drug without injector pen
WEBAug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply ...
Eli Lilly: A Strong Buy Amidst Obesity Treatment Market …
WEB3 days ago · In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,150.00. Alec Stranahan ...
Eli Lilly and Company (LLY) Latest Stock News & Headlines
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.